Navigation Links
Inovio Pharmaceuticals' Malaria DNA Vaccine Demonstrates Robust Immune Responses in Animal Models
Date:8/15/2013

r T-cells," in the liver, which is essential for rapid elimination of liver-stage malaria parasites. The Inovio DNA/electroporation platform has demonstrated in prior preclinical and human studies the ability to induce potent immune responses to multiple antigens; in this study, robust and sustained antibody responses to all four malaria antigens were observed, a strong indication for a preventive response in humans.

Inovio plans to initiate a phase I/IIa clinical trial in 2014 to test Inovio's DNA vaccine and electroporation technology in approximately 30 individuals as part of a "challenge trial" involving controlled human malaria infection. Volunteers will be administered Inovio's vaccine, then exposed to the malaria parasite through the bite of infected mosquitoes to see whether this approach prevents infection. If deemed successful, this trial would provide valuable information that may further the development of a vaccine against malaria and lead to larger efficacy studies in the field.

Dr. J. Joseph Kim, President and CEO of Inovio, said, "Published data from two clinical studies has demonstrated that Inovio's products generated best-in-class T-cell immune responses. Using the same synthetic vaccine technology that produced clinical candidates against HPV, HIV, and influenza and achieved potent antibody and T-cell immune responses against these targets, we have now generated strong immunology data with our malaria vaccine in non-human primates. We are excited to advance toward the very important healthcare goal of conquering malaria."

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth,
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inovio Pharmaceuticals Reports 2013 Second Quarter Financial Results
2. Inovio Pharmaceuticals Responds to Market Activity
3. Inovio Pharmaceuticals Potent hTERT DNA Cancer Vaccine Shows Potential to Reduce Tumors and Prevent Tumor Recurrence
4. Synthetically Optimized HIF-1 Alpha DNA Delivered with Inovios Electroporation Technology Provides Significant Therapeutic Effects for Peripheral Arterial Disease in Animal Model
5. Todays Research: Inovio Pharma, Sequenom, Peregrine Pharma, Onyx Pharma, and Optimer Pharma
6. Inovio Pharmaceuticals to Present at OneMedForumNY 2013 Investor Conference
7. Inovios Universal H7N9 DNA Vaccine Generates First Protective Antibody Responses Against Virulent H7N9 Virus in 100% of Vaccinated Animals
8. Inovio Pharmaceuticals DNA Vaccine Against Ebola and Marburg Filoviruses Provides Complete Protection in Preclinical Challenge Study
9. Inovio Pharmaceuticals Universal H1N1 Influenza Vaccine Achieves Protective Immune Responses Comparable to Conventional Vaccine in Phase I Study
10. Inovio Pharmaceuticals Recognized With "Best Therapeutic Vaccine" and "Best Early Stage Biotech" Awards at World Vaccine Congress 2013
11. Inovio Pharmaceuticals & U.S. Army Receive $3.5 Million Biodefense Grant to Further Develop Mass Vaccination Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)...  Boston Children,s Hospital physicians report the first ... their anatomy before undergoing high-risk brain procedures. The ... the brain,s blood vessels) that posed special treatment ... Journal of Neurosurgery: Pediatrics , the physicians ... resins to create custom, high-fidelity models of the ...
(Date:7/31/2015)... 31, 2015  Xcelience, a contract development and ... made a structured cash investment in Powdersize, a ... milling, micronization and powder size classification within the ... business while simultaneously adding a complete set of ... capabilities. "As we continue to ...
(Date:7/31/2015)... , July 31, 2015 Egalet ... integrated specialty pharmaceutical company focused on developing, manufacturing ... closing of its previously announced underwritten public offering ... a public offering price of $11.25 per share. ... included 1,000,000 shares issued upon the exercise in ...
Breaking Medicine Technology:3D Printing Helps Doctors Rehearse Complex Brain Procedures 23D Printing Helps Doctors Rehearse Complex Brain Procedures 33D Printing Helps Doctors Rehearse Complex Brain Procedures 4Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4
... Medicated Arthri-Zen Relief Cream(R) Clinically Shown to Work for up ... Americans suffer from the aches and pains that come with ... effective ways to get fast relief from arthritis pain is ... the relief tends to be short-lived. Many people find that ...
... economic slowdown, America,s pharmaceutical research and biotechnology companies ... the research and development of new life-changing medicines ... billion from 2007, according to analyses by the ... Burrill & Company. PhRMA-member companies alone invested ...
Cached Medicine Technology:Fast-Acting, Long-Lasting Topical Relief From Arthritis Pain 2Fast-Acting, Long-Lasting Topical Relief From Arthritis Pain 3R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges 2R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges 3R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges 4
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned hot ... their new type of sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) ... To commemorate introduction of this new type of sod, Super-Sod is giving away red ...
(Date:7/31/2015)... (PRWEB) , ... August 01, 2015 , ... Super Bowl 50 will emanate ... Football League’s biggest day each year is the Super Bowl. In the two weeks that ... place from the host venue. The 2016 Super Bowl game will mark the 50th time ...
(Date:7/31/2015)... ... July 31, 2015 , ... Precision Aesthetics is New York’s only Thermage ... also the first provider of Exilis non-surgical fat reduction in New York. Due ... attracted a large International clientele. Many patients travel to New York to get ...
(Date:7/31/2015)... Alexandria, VA (PRWEB) , ... July 31, 2015 ... ... Foundation) introduced its new store run by GoodThreads. The store can be accessed ... products and designs, many of which are customizable. The best part: whenever a ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Sculpted Contours Luxury ... CoolSmooth PRO this week. Zeltiq Aesthetics released this new applicator in the United ... 2014 for treating the outer thighs. The original applicator required a 2 hour ...
Breaking Medicine News(10 mins):Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3
... Australia, April 20 Progen Pharmaceuticals Limited (ASX: PGL; ... that shows its epigenetic technology successfully inhibits tumor ... Progen,s collaborators at the 100th Annual American Association ... was effective in ,switching on, important anti-cancer genes ...
... with the power and influence to improve the healthcare ... to reform the nation,s healthcare system dominate Modern ... Healthcare for 2009. Among those making the list are ... Services Department; Nancy-Ann DeParle, director of the newly created ...
... - A national team of researchers led by Mayo Clinic ... more likely to have similar DNA changes or variants in ... have the cancer. , The findings, being presented at the ... an independent validation of an earlier European study that found ...
... Southern California have identified a new drug compound that ... without the negative side effects typically associated with Cox-2 ... to have a strong anti-tumor effect while also attacking ... tumor growth, according to data presented at the AACR ...
... Universal Health Realty Income Trust (NYSE: UHT ) ... C. Stein as a Trustee. Mr. Stein becomes the seventh ... Trustee. Mr. Stein, 50, is currently president and ... real estate company specializing in the acquisition, development, leasing and ...
... to Provide Free Counseling to Military Members, Veterans, and ... is honoring National Volunteer Week (April 19-25, 2009) with ... professionals to join the Give an Hour(TM) network to ... Hour(TM) is a nonprofit organization that has created a ...
Cached Medicine News:Health News:Progen Technology Switches on Cancer Fighting Genes and Inhibits Tumor Growth 2Health News:Progen Technology Switches on Cancer Fighting Genes and Inhibits Tumor Growth 3Health News:Progen Technology Switches on Cancer Fighting Genes and Inhibits Tumor Growth 4Health News:Health Reformers Dominate Magazine's List of the Top 25 Women in Healthcare 2Health News:Mayo Clinic-led researchers confirm gene variants associated with the most common adult leukemia 2Health News:USC researchers develop new drug to target tumor cells and blood vessels 2Health News:Give an Hour(TM) Honors National Volunteer Week with Call to Service 2
Conforms to the convexity of the lens providing easier access to anterior capsule. Reduces pontential of corneal touch. 25G x 5/8in (.50 x 16mm)...
... designed for LASIK surgery and other ... irrigate the corneal interface and/or stromal ... under the flap and helps elevate ... multi-directional irrigation. Two 25G (.50mm) parallel ...
... product designed for LASIK surgery and ... to irrigate the corneal interface and/or ... insertion under the flap and helps ... provide multi-directional irrigation. 25G x 7/8in ...
Cannula tip is specially rounded, extra smooth for safe insertion through wound and manipulation in the anterior chamber. 23G x 7/8 in (.60 x 22mm). .3mm end port. Olive shape tip is 2mm long x 1mm w...
Medicine Products: